Table 2 Treatment characteristics

Recurrence population, excluding DM only

n = 40

(%)

IMRT Dose and Fractionation

Median Dose (range), Gy

66

(60-72.6)

Median Fractionation (range)

30

(30–33)

Boost to High-Risk Volumes

66–72.6 Gy

29

(72.5)

Concurrent Systemic Therapy

Cisplatin

13

(32.5)

Carboplatin

3

(7)

Cetuximab

1

(2.5)

None

23

(56)

 Due to comorbidities

9

(39)

Time to Initiation of postoperative (C)RT

≤ 6 weeks

16

(39)

> 6 weeks

24

(61)

Total Treatment Package Time

Median (IQR), days

92

(80–104)

< 77 days

3

(7.5)

77–85 days

12

(30.0)

86–100 days

12

(30.0)

> 100 days

13

(32.5)

Recurrence population, including DM only

n = 56

(%)

Salvage therapy

Local therapy

23

(41)

Resection of isolated pulmonary metastases

3

Re-Resection local/regional

19

Re-RT

1

Systemic therapy

21

(38)

None/BSC

8

(14)

Unknown

4

(7)

Neck dissection

Bilateral

41

(73.0)

Unilateral

13

(23.0)

None

2

(4.0)

Neck irradiation

Bilateral

50

(89.0)

Unilateral

3

(5.5)

None

3

(5.5)

Entire population

n = 203

(%)

Neck dissection

Bilateral

130

(64)

Ipsilateral

67

(33)

None

6

(3)

Neck irradiation

Bilateral

156

(77)

Ipsilateral

34

(17)

None

13

(6)